94 related articles for article (PubMed ID: 7955801)
1. Pharmacogenetic characteristics of the eosinophilia-myalgia syndrome.
Flockhart DA; Clauw DJ; Sale EB; Hewett J; Woosley RL
Clin Pharmacol Ther; 1994 Oct; 56(4):398-405. PubMed ID: 7955801
[TBL] [Abstract][Full Text] [Related]
2. Activity of oxidative routes of metabolism of debrisoquin, mephenytoin, and dapsone is unrelated to the pathogenesis of vinyl chloride-induced disease.
Black C; May G; Csuka ME; Lupoli S; Wilkinson GR; Branch RA
Clin Pharmacol Ther; 1992 Dec; 52(6):659-67. PubMed ID: 1458774
[TBL] [Abstract][Full Text] [Related]
3. Scleroderma is associated with differences in individual routes of drug metabolism: a study with dapsone, debrisoquin, and mephenytoin.
May DG; Black CM; Olsen NJ; Csuka ME; Tanner SB; Bellino L; Porter JA; Wilkinson GR; Branch RA
Clin Pharmacol Ther; 1990 Sep; 48(3):286-95. PubMed ID: 2401127
[TBL] [Abstract][Full Text] [Related]
4. Debrisoquin and mephenytoin hydroxylation phenotypes and CYP2D6 genotype in patients treated with neuroleptic and antidepressant agents.
LLerena A; Herraíz AG; Cobaleda J; Johansson I; Dahl ML
Clin Pharmacol Ther; 1993 Dec; 54(6):606-11. PubMed ID: 7903915
[TBL] [Abstract][Full Text] [Related]
5. Frequency distribution of dapsone N-hydroxylase, a putative probe for P4503A4 activity, in a white population.
May DG; Porter J; Wilkinson GR; Branch RA
Clin Pharmacol Ther; 1994 May; 55(5):492-500. PubMed ID: 8181193
[TBL] [Abstract][Full Text] [Related]
6. Molecular mechanisms of genetic polymorphisms of drug metabolism.
Meyer UA; Zanger UM
Annu Rev Pharmacol Toxicol; 1997; 37():269-96. PubMed ID: 9131254
[TBL] [Abstract][Full Text] [Related]
7. Dapsone N-acetylation, metoprolol alpha-hydroxylation, and S-mephenytoin 4-hydroxylation polymorphisms in an Indonesian population: a cocktail and extended phenotyping assessment trial.
Setiabudy R; Kusaka M; Chiba K; Darmansjah I; Ishizaki T
Clin Pharmacol Ther; 1994 Aug; 56(2):142-53. PubMed ID: 8062490
[TBL] [Abstract][Full Text] [Related]
8. Debrisoquine/sparteine hydroxylation genotype and phenotype: analysis of common mutations and alleles of CYP2D6 in a European population.
Broly F; Gaedigk A; Heim M; Eichelbaum M; Morike K; Meyer UA
DNA Cell Biol; 1991 Oct; 10(8):545-58. PubMed ID: 1681816
[TBL] [Abstract][Full Text] [Related]
9. Validation of the five-drug "Pittsburgh cocktail" approach for assessment of selective regulation of drug-metabolizing enzymes.
Frye RF; Matzke GR; Adedoyin A; Porter JA; Branch RA
Clin Pharmacol Ther; 1997 Oct; 62(4):365-76. PubMed ID: 9357387
[TBL] [Abstract][Full Text] [Related]
10. CYP2C19 genotype and S-mephenytoin 4'-hydroxylation phenotype in a Chinese Dai population.
He N; Yan FX; Huang SL; Wang W; Xiao ZS; Liu ZQ; Zhou HH
Eur J Clin Pharmacol; 2002 Apr; 58(1):15-8. PubMed ID: 11956668
[TBL] [Abstract][Full Text] [Related]
11. Candidate genetic modifiers of individual susceptibility to renal cell carcinoma: a study of polymorphic human xenobiotic-metabolizing enzymes.
Longuemaux S; Deloménie C; Gallou C; Méjean A; Vincent-Viry M; Bouvier R; Droz D; Krishnamoorthy R; Galteau MM; Junien C; Béroud C; Dupret JM
Cancer Res; 1999 Jun; 59(12):2903-8. PubMed ID: 10383153
[TBL] [Abstract][Full Text] [Related]
12. S-mephenytoin hydroxylation phenotypes in a Swedish population determined after coadministration with debrisoquin.
Sanz EJ; Villén T; Alm C; Bertilsson L
Clin Pharmacol Ther; 1989 May; 45(5):495-9. PubMed ID: 2721104
[TBL] [Abstract][Full Text] [Related]
13. Importance of genetic factors in the regulation of diazepam metabolism: relationship to S-mephenytoin, but not debrisoquin, hydroxylation phenotype.
Bertilsson L; Henthorn TK; Sanz E; Tybring G; Säwe J; Villén T
Clin Pharmacol Ther; 1989 Apr; 45(4):348-55. PubMed ID: 2495208
[TBL] [Abstract][Full Text] [Related]
14. Single-dose kinetics of clomipramine: relationship to the sparteine and S-mephenytoin oxidation polymorphisms.
Nielsen KK; Brøsen K; Hansen MG; Gram LF
Clin Pharmacol Ther; 1994 May; 55(5):518-27. PubMed ID: 8181196
[TBL] [Abstract][Full Text] [Related]
15. Eosinophilia-myalgia syndrome not associated with the ingestion of nutritional supplements.
Clauw DJ; Flockhart DA; Mullins W; Katz P; Medsger TA
J Rheumatol; 1994 Dec; 21(12):2385-7. PubMed ID: 7699648
[TBL] [Abstract][Full Text] [Related]
16. Effect of conjugated equine estrogens on oxidative metabolism in middle-aged and elderly postmenopausal women.
O'Connell MB; Frye RF; Matzke GR; St Peter JV; Willhite LA; Welch MR; Kowal P; LaValleur J
J Clin Pharmacol; 2006 Nov; 46(11):1299-307. PubMed ID: 17050794
[TBL] [Abstract][Full Text] [Related]
17. Pharmacogenetic profile of xenobiotic enzyme metabolism in survivors of the Spanish toxic oil syndrome.
Ladona MG; Izquierdo-Martinez M; Posada de la Paz MP; de la Torre R; Ampurdanés C; Segura J; Sanz EJ
Environ Health Perspect; 2001 Apr; 109(4):369-75. PubMed ID: 11335185
[TBL] [Abstract][Full Text] [Related]
18. Validation of incorporating flurbiprofen into the Pittsburgh cocktail.
Zgheib NK; Frye RF; Tracy TS; Romkes M; Branch RA
Clin Pharmacol Ther; 2006 Sep; 80(3):257-63. PubMed ID: 16952492
[TBL] [Abstract][Full Text] [Related]
19. S-mephenytoin 4-hydroxylase is inherited as an autosomal-recessive trait in Japanese families.
Ward SA; Goto F; Nakamura K; Jacqz E; Wilkinson GR; Branch RA
Clin Pharmacol Ther; 1987 Jul; 42(1):96-9. PubMed ID: 3595072
[TBL] [Abstract][Full Text] [Related]
20. Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin.
Bertilsson L; Lou YQ; Du YL; Liu Y; Kuang TY; Liao XM; Wang KY; Reviriego J; Iselius L; Sjöqvist F
Clin Pharmacol Ther; 1992 Apr; 51(4):388-97. PubMed ID: 1345344
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
